Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
Shattuck Labs, Inc. reported that Chief Executive Officer and director Taylor Schreiber received a new stock option grant on January 10, 2026. The option gives him the right to buy 1,548,300 shares of Shattuck Labs common stock at an exercise price of $4.75 per share and expires on January 10, 2036.
According to the vesting schedule, one quarter of the option will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, as long as he continues serving the company. After this grant, he beneficially owns 1,548,300 derivative securities directly.
Shattuck Labs, Inc. has filed a shelf registration to offer up to $200,000,000 in aggregate of common stock, preferred stock, debt securities, warrants and units from time to time. Each offering will have its own prospectus supplement detailing specific terms, pricing and the method of sale, which may include underwritten offerings, direct sales or at-the-market transactions on The Nasdaq Global Select Market under the symbol STTK. The company develops potential treatments for inflammatory and immune-mediated diseases, led by its SL-325 antibody program. Net proceeds from future offerings are expected to fund ongoing and planned clinical trials, development of additional product candidates, and general corporate and working capital needs, with possible use for licensing or acquisitions.
Shattuck Labs (STTK) filed an 8-K/A (Amendment No. 1) to correct typographical errors in a previously filed 8-K. The amendment covers Item 2.02 relating to a press release announcing financial results for the quarter ended September 30, 2025, which is furnished as Exhibit 99.1.
The company notes that, under General Instruction B.2, the Item 2.02 information and Exhibit 99.1 are furnished, not filed. The filing also lists Exhibit 104, the cover page formatted in Inline XBRL.
Shattuck Labs (STTK) reported Q3 2025 results showing a smaller loss as operating expenses declined and it recognized license revenue. License and collaboration revenue was $1,000, versus $2,997 a year ago, reflecting a one-time license to Kayak Therapeutics. Research and development expense fell to $7,618 from $16,313, and general and administrative expense was $4,098 versus $4,604. Net loss narrowed to $10,056 from $16,675.
Cash and cash equivalents were $42,548 and investments were $43,584 as of September 30, 2025, for total liquid resources of about $86.1 million. Management states this is sufficient to fund projected operations for at least the next twelve months. During August 2025, the company raised $44,480 net in a private placement of common stock, pre-funded warrants, and common stock warrants tied to future clinical data disclosure milestones. Shares outstanding were 63,151,789 at quarter-end; the company disclosed 63,279,843 outstanding as of October 23, 2025.
Shattuck Labs (STTK) furnished an update under Item 2.02, announcing it issued a press release with financial results for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1. The company states this information is furnished, not filed, under General Instruction B.2, meaning it is not subject to Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Shattuck Labs, Inc. files a Form S-3 shelf registration that describes an offering including Common Stock, Pre-Funded Warrants and Common Warrants and incorporates by reference prior SEC reports and a Form 8-K filed August 5, 2025. The filing lists a detailed beneficial ownership table showing pre- and post-offering share counts and percentages for multiple investors and insiders, including a holder with 36,879,576 shares (39.35%). The document discloses a securities purchase agreement dated August 4, 2025, exhibits including certificate and bylaw amendments, forms of warrants and registration rights, legal and accounting opinions, and filing fee information. Signatures from the CEO and directors are included with dates in September 2025.
OrbiMed-affiliated entities disclosed acquiring an aggregate of 6,306,127 Shares of Shattuck Labs, representing 9.99% of the outstanding common stock on a post-PIPE basis. The holdings arise from the August 25, 2025 closing of a PIPE in which the issuer sold 15,225,158 Shares and pre-funded warrants and accompanying warrants aggregating potential issuance of 52,635,346 Shares. OrbiMed Private Investments IX, LP (OPI IX) purchased 5,255,106 Shares (≈9.99%) and OrbiMed Genesis Master Fund, L.P. (Genesis) purchased 1,051,021 Shares (≈1.67%).
The PIPE included pre-funded and common warrants but those warrants are subject to an exercise 9.99% blocker and are not presently exercisable. OrbiMed Advisors and its GP entities disclose shared voting and dispositive power over the shares held by the funds and note a board relationship via Director Mona Ashiya, who is obligated to transfer any director equity awards to OrbiMed-affiliated funds. A registration rights agreement was negotiated requiring the issuer to file a resale registration for the PIPE shares.
OrbiMed-affiliated reporting persons purchased securities of Shattuck Labs (STTK) in a private placement that closed on 08/25/2025. They acquired an aggregate of 6,306,127 shares and pre-funded warrants to buy up to 12,133,661 additional shares, plus common warrants exercisable for up to 18,439,799 shares. The price per share with a common warrant was $0.8677 and per pre-funded warrant with a common warrant was $0.8676. The pre-funded warrants are immediately exercisable subject to a 9.99% ownership blocker. Common warrants expire based on clinical-trial data disclosure timing described in the filing.
Shattuck Labs reported a private placement on 08/25/2025 in which accredited investors led by OrbiMed vehicles purchased an aggregate of 6,306,127 shares of common stock and received pre-funded warrants to buy up to 12,133,661 shares plus accompanying common warrants to buy up to 18,439,799 shares. The price per share with an accompanying common warrant was $0.8677; the pre-funded warrant price with an accompanying common warrant was $0.8676. Pre-funded warrants are immediately exercisable subject to a 9.99% beneficial ownership blocker. The report was filed by Mona Ashiya, identified as a director, who disclaims beneficial ownership of the securities except to the extent of pecuniary interest, and the securities are held of record by OrbiMed funds and related entities.
OrbiMed entities and OrbiMed Advisors LLC reported their relationship to Shattuck Labs (STTK) as directors but stated they do not beneficially own any securities of the issuer. The Form 3 lists three reporting entities at the same New York address and indicates the filing covers more than one reporting person. No non‑derivative or derivative holdings are reported.